<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>349</serviceExecutionTime><Drug id="84867"><DrugName>Vaxem HIB</DrugName><DrugNamesKey><Name id="43007881">Vaxem HIB</Name></DrugNamesKey><DrugSynonyms><Name><Value>Haemophilus influenzae B vaccine, Takeda/ Novartis</Value></Name><Name><Value>TAK-816</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Vaxem HIB</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Hib-CRM197 conjugate vaccine</Value></Name></DrugSynonyms><CompanyOriginator id="15385">Chiron Corp</CompanyOriginator><CompaniesSecondary><Company id="15385">Chiron Corp</Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Company id="23137">Novartis AG</Company><Company id="28355">GlaxoSmithKline plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="15385" type="Company"><TargetEntity id="5036161975" type="organizationId">Chiron Corp</TargetEntity></SourceEntity><SourceEntity id="20300" type="Company"><TargetEntity id="4295877353" type="organizationId">Takeda Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="145" type="ciIndication"><TargetEntity id="1410" type="siCondition"/></SourceEntity><SourceEntity id="1803" type="ciIndication"><TargetEntity id="G00" type="ICD10"/><TargetEntity id="320" type="ICD9"/><TargetEntity id="10027202" type="MEDDRA"/><TargetEntity id="D016920" type="MeSH"/><TargetEntity id="-373187665" type="omicsDisease"/><TargetEntity id="893" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="W">Withdrawn</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Bacterial meningitis - Germany - Mar-2003</FirstLaunched><FirstLaunched>Haemophilus influenzae infection - Germany - Mar-2003</FirstLaunched></PhaseHighestDetailed><IndicationsSecondary><Indication id="145">Haemophilus influenzae infection</Indication><Indication id="1803">Bacterial meningitis</Indication></IndicationsSecondary><ActionsSecondary><Action id="12371">Subunit vaccine</Action><Action id="12378">Prophylactic vaccine</Action></ActionsSecondary><Technologies><Technology id="596">Injectable formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="766">Parenteral formulation unspecified</Technology></Technologies><LastModificationDate>2018-12-03T09:28:27.000Z</LastModificationDate><ChangeDateLast>2018-01-03T00:00:00.000Z</ChangeDateLast><AddedDate>2013-05-04T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="28355" linkType="Company"&gt;GlaxoSmithKline&lt;/ulink&gt;, following the acquisition of vaccine business from &lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt; and its subsidiary &lt;ulink linkID="15385" linkType="Company"&gt;Chiron&lt;/ulink&gt; had developed and launched Vaxem HIB (TAK-816), a conjugate vaccine composed of Haemophilus influenzae capsular polysaccharides combined with detoxified diphtheria toxin, for the prevention of pediatric bacterial meningitis caused by Haemophilus influenzae type b [&lt;ulink linkID="484051" linkType="Reference"&gt;484051&lt;/ulink&gt;], [&lt;ulink linkID="1521722" linkType="Reference"&gt;1521722&lt;/ulink&gt;], [&lt;ulink linkID="1925893" linkType="Reference"&gt;1925893&lt;/ulink&gt;]. By March 2003, the vaccine was available in Germany [&lt;ulink linkID="484051" linkType="Reference"&gt;484051&lt;/ulink&gt;], [&lt;ulink linkID="1521722" linkType="Reference"&gt;1521722&lt;/ulink&gt;]. In March 2015, GSK acquired the vaccine business from Novartis [&lt;ulink linkID="1925893" linkType="Reference"&gt;1925893&lt;/ulink&gt;]. In November 2010, the vaccine was approved in China and it was assumed that launch took place shortly after [&lt;ulink linkID="1586985" linkType="Reference"&gt;1586985&lt;/ulink&gt;], [&lt;ulink linkID="1586986" linkType="Reference"&gt;1586986&lt;/ulink&gt;]. However in May 2017, GSK decided to discontinue the manufacture and supply of VAXEM HIB worldwide [&lt;ulink linkID="1925893" linkType="Reference"&gt;1925893&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Licensee &lt;ulink linkID="20300" linkType="Company"&gt;Takeda Pharmaceutical&lt;/ulink&gt; had previously developed the vaccine, for the prevention of pediatric bacterial meningitis caused by Haemophilus influenzae type b [&lt;ulink linkID="1012540" linkType="Reference"&gt;1012540&lt;/ulink&gt;], [&lt;ulink linkID="1729026" linkType="Reference"&gt;1729026&lt;/ulink&gt;]. In January 2016, the vaccine was approved in  Japan [&lt;ulink linkID="1729026" linkType="Reference"&gt;1729026&lt;/ulink&gt;]. However in May 2017, GSK terminated the distribution agreement with Takeda for Japan and as a result Takeda terminated the planned launch [&lt;ulink linkID="1925893" linkType="Reference"&gt;1925893&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;By March 2003, the vaccine was available in Germany [&lt;ulink linkID="484051" linkType="Reference"&gt;484051&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In September 2013, Takeda filed an NDA with the Japanese Ministry of Health, Labour and Welfare [&lt;ulink linkID="1200202" linkType="Reference"&gt;1200202&lt;/ulink&gt;]; in January 2014, Japanese approval was expected in the fiscal year 2014 [&lt;ulink linkID="1524161" linkType="Reference"&gt;1524161&lt;/ulink&gt;]. In August 2014, the Pharmaceutical Affairs and Food Sanitation Council's Second Committee on Drugs was to discuss the application at a meeting scheduled for September 05, 2014 [&lt;ulink linkID="1598363" linkType="Reference"&gt;1598363&lt;/ulink&gt;]; in September 2014, the drug was recommended for approval, but final approval was postponed due to an error in the safety information in foreign market surveillance. In June 2015, the Ministry of Health, Labour and Welfare's Second Committee on New Drugs, Pharmaceutical Affairs and Food Sanitation Council again put approval of the drug on hold [&lt;ulink linkID="1664716" linkType="Reference"&gt;1664716&lt;/ulink&gt;]. In January 2016, the Japanese Ministry of Health, Labour and Welfare approved the NDA  for the prevention of infections caused by caused by Haemophilus influenzae type b [&lt;ulink linkID="1729026" linkType="Reference"&gt;1729026&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In November 2010, the vaccine was approved in China; it was assumed that launch took place shortly after [&lt;ulink linkID="1586985" linkType="Reference"&gt;1586985&lt;/ulink&gt;], [&lt;ulink linkID="1586986" linkType="Reference"&gt;1586986&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In June 2011, Takeda initiated a phase III study in Japan [&lt;ulink linkID="1200202" linkType="Reference"&gt;1200202&lt;/ulink&gt;]. By September 2013, a multicenter, randomized, double-blind, parallel-group, comparative-study, phase III trial in Japanese children (n = 416) had been completed. In the study, the vaccine demonstrated positive results on its safety and immunogenicity [&lt;ulink linkID="1481200" linkType="Reference"&gt;1481200&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2010, Novartis initiated a randomized, single-blind, parallel-group phase III trial (&lt;ulink linkID="71605" linkType="Protocol"&gt;NCT01226953&lt;/ulink&gt;; V37_07E1) in China to evaluate the safety and immunogenicity of Vaxem HIB, as compared to &lt;ulink linkID="64233" linkType="Drug"&gt;Hiberix&lt;/ulink&gt;, in  children      (n = 660) 365 to 569 days of age. In March 2011, the trial was completed [&lt;ulink linkID="1586999" linkType="Reference"&gt;1586999&lt;/ulink&gt;]. In August 2014, Novartis planned to initiate a randomized, open-label, parallel-group, extension phase IIIb trial (&lt;ulink linkID="187536" linkType="Protocol"&gt;NCT02139228&lt;/ulink&gt;; V37_07E2; CTR20140433) in China to  evaluate the persistency of immune response of Vaxem HIB   by      assessing anti-PRP antibody levels in children who had attended the  former trial four years ago [&lt;ulink linkID="1587000" linkType="Reference"&gt;1587000&lt;/ulink&gt;], [&lt;ulink linkID="1587002" linkType="Reference"&gt;1587002&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November  2008, Novartis initiated a randomized, single-blind,  parallel-group phase III trial (&lt;ulink linkID="62500" linkType="Protocol"&gt;NCT00808392&lt;/ulink&gt;; M37P2) in China to evaluate the safety and immunogenicity of Vaxem HIB in healthy children (n = 916) aged 2 to 4 months. In February 2009, the trial was completed [&lt;ulink linkID="1587012" linkType="Reference"&gt;1587012&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2010, phase I development was underway in Japan [&lt;ulink linkID="1100211" linkType="Reference"&gt;1100211&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="CN">China</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2017-05-09T00:00:00.000Z</StatusDate><Source id="1925893" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="CN">China</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1803">Bacterial meningitis</Indication><StatusDate>2017-05-09T00:00:00.000Z</StatusDate><Source id="1925893" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1803">Bacterial meningitis</Indication><StatusDate>2017-05-09T00:00:00.000Z</StatusDate><Source id="1925893" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2017-05-09T00:00:00.000Z</StatusDate><Source id="1925893" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2017-05-09T00:00:00.000Z</StatusDate><Source id="1925893" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1803">Bacterial meningitis</Indication><StatusDate>2017-05-09T00:00:00.000Z</StatusDate><Source id="1925893" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="DE">Germany</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate>2015-03-31T00:00:00.000Z</StatusDate><Source id="1925893" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2015-03-31T00:00:00.000Z</StatusDate><Source id="1925893" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="DE">Germany</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2015-03-31T00:00:00.000Z</StatusDate><Source id="1925893" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate>2015-03-31T00:00:00.000Z</StatusDate><Source id="1925893" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2009-05-26T00:00:00.000Z</StatusDate><Source id="1012540" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate>2009-05-26T00:00:00.000Z</StatusDate><Source id="1012540" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2010-05-12T00:00:00.000Z</StatusDate><Source id="1100211" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate>2010-05-12T00:00:00.000Z</StatusDate><Source id="1100211" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate>2011-06-15T00:00:00.000Z</StatusDate><Source id="1200202" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2011-06-15T00:00:00.000Z</StatusDate><Source id="1200202" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2010-11-10T00:00:00.000Z</StatusDate><Source id="1586985" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate>2010-11-10T00:00:00.000Z</StatusDate><Source id="1586985" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2008-11-30T00:00:00.000Z</StatusDate><Source id="1587012" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate>2008-11-30T00:00:00.000Z</StatusDate><Source id="1587012" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate>2013-09-26T00:00:00.000Z</StatusDate><Source id="1481200" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2013-09-26T00:00:00.000Z</StatusDate><Source id="1481200" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2010-12-31T00:00:00.000Z</StatusDate><Source id="1586986" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate>2003-03-07T00:00:00.000Z</StatusDate><Source id="484051" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate>2010-12-31T00:00:00.000Z</StatusDate><Source id="1586986" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2003-03-07T00:00:00.000Z</StatusDate><Source id="484051" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2015-03-31T00:00:00.000Z</StatusDate><Source id="1925893" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate>2015-03-31T00:00:00.000Z</StatusDate><Source id="1925893" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate>2015-03-31T00:00:00.000Z</StatusDate><Source id="1925893" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2015-03-31T00:00:00.000Z</StatusDate><Source id="1925893" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1803">Bacterial meningitis</Indication><StatusDate>2016-01-22T00:00:00.000Z</StatusDate><Source id="1729026" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2016-01-22T00:00:00.000Z</StatusDate><Source id="1729026" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="124657" title="Takeda to develop Novartis' Vaxem Hib     "/></Deals><PatentFamilies><PatentFamily id="3185522" number="WO-2017144394" title="Vaccine"/><PatentFamily id="660856" number="WO-2006110413" title="Haemophilus influenzae type B"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The Institute for Genomic Research" id="21076"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>